James Bowen, MD
Neurology · Kirkland, WANPI 1124072434
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $244,699 of the $378,980 with a category attached, or 64.6%. 12 manufacturers reported payments, led by Biogen at 41.7% of the total. Reporting peaked in 2019 at $147,660 and has fallen 94.5% since, to $8,092 in 2024. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $1131.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$158K
- Genentech USA, Inc.$52K
- Bristol Myers Squibb$50K
- E.r. Squibb & Sons, L.L.C.$49K
- Novartis$47K
- EMD Serono, Inc.$8K
- plus $15K from 6 others
Across 271 payments — averaging $6978.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$838K
- AbbVie$308K
- Biogen$240K
- Alkermes, Inc.$225K
- Roche Products Limited$122K
- Novartis$80K
- plus $78K from 3 others
What the payments were for
- Consulting fees$72,99219%
- Speaking & faculty fees$244,69965%
- Grants$27,0007%
- Travel & lodging$25,2227%
- Food & beverage$9,0372%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 126 | $158,075 |
| Genentech USA, Inc. | 44 | $52,474 |
| Bristol Myers Squibb | 44 | $49,578 |
| E.r. Squibb & Sons, L.L.C. | 39 | $48,781 |
| Novartis | 52 | $46,932 |
| EMD Serono, Inc. | 11 | $8,286 |
| Novartis Pharma AG | 3 | $7,448 |
| TG Therapeutics, Inc. | 8 | $2,216 |
| Sanofi | 1 | $2,000 |
| Genentech, Inc. | 5 | $1,689 |
| ANI Pharmaceuticals, Inc. | 1 | $1,400 |
| AstraZeneca | 1 | $102 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$378,980 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 65 | $456,047 |
| FingolimodFingolimod Hcl | 144 | $436,149 |
| GilenyaFingolimod Hcl | 28 | $390,581 |
| Avonex (4 Pack)Interferon Beta-1a | 34 | $363,485 |
| RebifInterferon Beta-1a/Albumin | 23 | $273,193 |
| TecfideraDimethyl Fumarate | 27 | $237,835 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 15 | $188,239 |
| Glatiramer Acetate | 70 | $171,917 |
| VumerityDiroximel Fumarate | 16 | $127,914 |
| Dimethyl Fumarate | 77 | $54,591 |
| Dalfampridine ErDalfampridine | 91 | $41,211 |
| GlatopaGlatiramer Acetate | 12 | $31,344 |
| Baclofen | 192 | $7,321 |
| Modafinil | 104 | $7,259 |
| Gabapentin | 161 | $5,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera, Vumerity | $158,075 | $729,23377 claims |
| NovartisGilenya | $46,932 | $390,58128 claims |
| EMD Serono, Inc.Rebif | $8,286 | $273,19323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Kirkland
- Pinky AgarwalKirkland$795K
- Jason PoonKirkland$102K
- Arash FazlKirkland$71K
- James SongKirkland$31K
- Casey NazorKirkland$10K
- Daniel BurdickKirkland$6K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.